Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRDF Cardiff Oncology, Inc.

Trading 12-22 09:55:53 EST

2.67

+0.10

+3.89%

High2.72	Low2.53	Vol220.07K
Open2.54	D1 Closing2.57	Amplitude7.20%
Mkt Cap179.85M	Tradable Cap175.50M	Total Shares67.36M
T/O575.13K	T/O Rate0.33%	Tradable Shares65.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRDF","market":"US","secType":"STK","nameCN":"Cardiff Oncology, Inc.","latestPrice":2.67,"timestamp":1766415347382,"preClose":2.57,"halted":0,"volume":220073,"delay":0,"floatShares":65730400,"shares":67360564,"eps":-0.793959,"marketStatus":"Trading","change":0.1,"latestTime":"12-22 09:55:53 EST","open":2.54,"high":2.715,"low":2.53,"amount":575130.5914844,"amplitude":0.071984,"askPrice":2.68,"askSize":2900,"bidPrice":2.66,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-0.793959,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":2.57,"preHourTrading":{"tag":"盘前","latestPrice":2.51,"preClose":2.57,"latestTime":"09:25 EST","volume":2032,"amount":5087.918704,"timestamp":1766413500034},"postHourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.57,"latestTime":"19:56 EST","volume":26486,"amount":67744.07,"timestamp":1766192197280},"volumeRatio":2.964992,"impliedVol":0.847,"impliedVolPercentile":0.424},"requestUrl":"/m/hq/s/CRDF","defaultTab":"news","newsList":[{"id":"2590365993","title":"Cardiff Oncology Announces New Clinical Data on Onvansertib in Chronic Myelomonocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365993","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365993?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227909,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc. has announced that clinical data from an investigator-sponsored trial of onvansertib in chronic myelomonocytic leukemia  will be presented in a poster session at the 67th American Society of Hematology  Annual Meeting. The presentation is scheduled for December 8, 2025. The abstract related to this trial is available on the ASH Annual Meeting website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3ccy8j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4139","SG9999014013.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","SG9999014021.USD","SG9999014039.USD","CRDF","BK4588","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2590365604","title":"Cardiff Oncology Announces Clinical Data From Investigator-Sponsored Trial With Onvansertib in Chronic Myelomonocytic Leukemia at Ash 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365604?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA4PRFNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2589433726","title":"Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2589433726","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589433726?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:00","pubTimestamp":1765195218,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc., a clinical-stage biotechnology company focused on developing novel cancer therapies, will present and host one-on-one meetings at Sidoti's Year-End Virtual Investor Conference, taking place from December 10-11, 2025. CEO Mark Erlander, PhD, is scheduled to present on December 11, 2025, at 4:00 PM ET. Interested parties can register and access the live webcast through the Events section of the Cardiff Oncology website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL54BYM0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","BK4585","SG9999014021.USD","BK4139","CRDF","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2585618044","title":"Cardiff Oncology to Present at Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585618044","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585618044?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985628,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference, taking place from December 2-4, 2025. Company CEO Mark Erlander, PhD, is scheduled to present on December 2, 2025, at 9:30 AM ET. The event will include a fireside chat and one-on-one investor meetings, with a live webcast available through the Cardiff Oncology website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL3lbdmv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","CRDF","NDAQ","BK4139","BK4588","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582594359","title":"Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), BioLife Solutions (BLFS) and Cardiff Oncology (CRDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582594359","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582594359?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:30","pubTimestamp":1762849820,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nkarta (NKTX – Research Report), BioLife Solutions (BLFS – Resear...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nkarta-nktx-biolife-solutions-blfs-and-cardiff-oncology-crdf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nkarta-nktx-biolife-solutions-blfs-and-cardiff-oncology-crdf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XLV","LABU","BK4198","BLFS","LU1169590202.USD","LU1169589451.USD","BK4139","XBI","LU0029874061.USD","BK4581","NKTX","BK4505","BK4121","LU0128526141.USD","BK4585","CRDF","HCSG","BK4588"],"gpt_icon":0},{"id":"2582808570","title":"Analysts Are Bullish on These Healthcare Stocks: Myomo (MYO), Cardiff Oncology (CRDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582808570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582808570?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:11","pubTimestamp":1762787473,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Myomo (MYO – Research Report), Cardiff Oncology (CRD...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-myomo-myo-cardiff-oncology-crdf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-myomo-myo-cardiff-oncology-crdf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4137","LU0128526141.USD","CRDF","LABU","LU0029874061.USD","BK4585","BK4588","MYO","XLV","HCSG","XBI","BK4139","BK4112","BK4581"],"gpt_icon":0},{"id":"2581046253","title":"Cardiff Oncology posts smaller-than-expected Q3 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046253","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046253?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:10","pubTimestamp":1762467056,"startTime":"0","endTime":"0","summary":"Cardiff Oncology posts smaller-than-expected Q3 lossOverviewCardiff Oncology Q3 net loss is smaller-than-expectations, reflecting better operational performanceCompany's Q3 operating expenses decrease","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1L0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2581043239","title":"Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581043239","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581043239?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:37","pubTimestamp":1762465055,"startTime":"0","endTime":"0","summary":"Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15.42 percent. This is a 32 percent increase over losses of $(0.25) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48705337/cardiff-oncology-q3-eps-0-17-beats-0-20-estimate-sales-120-000k-beat-112-500k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2580226532","title":"Cardiff Oncology Inc  expected to post a loss of 20 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580226532","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580226532?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:48","pubTimestamp":1762206486,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc  expected to post a loss of20cents a share - Earnings Preview Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to  show a fall in quarterly revenue when it reports  results on Nove","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF2DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2563665000","title":"Cardiff Oncology Inc. to Participate in H.C. Wainwright Global Investment Conference with CEO Mark Erlander Presenting","url":"https://stock-news.laohu8.com/highlight/detail?id=2563665000","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563665000?lang=en_us&edition=fundamental","pubTime":"2025-08-29 04:05","pubTimestamp":1756411520,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc., a clinical-stage biotechnology company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The event will feature a Fireside Chat and 1x1 meetings, with CEO Mark Erlander presenting. Interested parties can register and access the live webcast through the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on August 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL30QCmm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","CRDF","BK4588","IE00BGHQF748.EUR","NDAQ","BK4112","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2555649820","title":"BRIEF-Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004)","url":"https://stock-news.laohu8.com/highlight/detail?id=2555649820","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555649820?lang=en_us&edition=fundamental","pubTime":"2025-07-30 05:26","pubTimestamp":1753824418,"startTime":"0","endTime":"0","summary":"BRIEF-Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004)Cardiff Oncology Inc CRDF.O:CARDIFF ONCOLOGY ANNOUNCES POSITIVE DATA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nTUA5CTGCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2555069633","title":"Cardiff Oncology Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $121.00K Beat $92.86K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2555069633","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555069633?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:14","pubTimestamp":1753820078,"startTime":"0","endTime":"0","summary":"Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 19.23 percent increase over losses of $(0.26) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/07/46705397/cardiff-oncology-q2-eps-0-21-misses-0-20-estimate-sales-121-00k-beat-92-86k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF"],"gpt_icon":0},{"id":"2555206986","title":"Cardiff Oncology Inc - Trial Shows 49% Orr in 30Mg Onvansertib Dose Arm","url":"https://stock-news.laohu8.com/highlight/detail?id=2555206986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555206986?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:07","pubTimestamp":1753819620,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nTUA5CTGCF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2555206952","title":"Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)","url":"https://stock-news.laohu8.com/highlight/detail?id=2555206952","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555206952?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:07","pubTimestamp":1753819620,"startTime":"0","endTime":"0","summary":"– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/29/3123615/0/en/Cardiff-Oncology-Announces-Positive-Data-from-Ongoing-Randomized-Phase-2-First-line-RAS-mutated-mCRC-Clinical-Trial-CRDF-004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861220033.SGD","BK4213","LU1548497426.USD","ON","BK4585","BK4195","LU2298322129.HKD","LU1861219969.SGD","BK4211","LU1854104046.USD","ETS","ITT","BK4605","CR","CRDF","LU1720051108.HKD","LU0054578231.USD","LU1720051017.SGD","BK4161","LU1854103824.USD","LU1978683503.SGD","PFS","LU2357305700.SGD","IE00BZ199S13.USD","LU1861215975.USD","LU0124384867.USD","PR","LU2360107325.USD","IE00BD6J9T35.USD","LU0348723411.USD","BK4139","LU1861214812.USD","LU0724618433.USD","BK4588","LU0053671581.USD","BK4141","ORR","BK4512"],"gpt_icon":0},{"id":"2555306185","title":"Cardiff Oncology Inc - Has $71 Mln Cash as of June 30, Runway Into Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2555306185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555306185?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:05","pubTimestamp":1753819501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nPLX4CB328:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2555061851","title":"Cardiff Oncology Inc - Completes Enrollment in Phase 2 Crdf-004 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2555061851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555061851?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:05","pubTimestamp":1753819501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nPLX4CB328:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2550452578","title":"Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Roger Sidhu, Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550452578","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550452578?lang=en_us&edition=fundamental","pubTime":"2025-07-09 04:06","pubTimestamp":1752005173,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing lists Roger Sidhu as the beneficial owner, serving as the Chief Medical Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL3mXfgk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"gpt_icon":0},{"id":"2550652056","title":"Cardiff Oncology Initiated at Buy by Ladenburg Thalmann","url":"https://stock-news.laohu8.com/highlight/detail?id=2550652056","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550652056?lang=en_us&edition=fundamental","pubTime":"2025-07-09 02:54","pubTimestamp":1752000840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRDF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2025 14:54 ET (18:54 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"2549432540","title":"ADVISORY-Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2549432540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549432540?lang=en_us&edition=fundamental","pubTime":"2025-07-08 21:26","pubTimestamp":1751981187,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawnJuly 8 (Reuters) - An alert on the global oncology market experiencing substantial growth from an FN Media Grou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA3YKH58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2091194634.USD","LU0972486137.USD","IE0034235188.USD","LU2114397693.USD","IE00B4R5TH58.HKD","LU0889566641.SGD","LU1057294990.SGD","LU1119994496.HKD","LU1291159041.SGD","LU0211326755.USD","LU0738911758.USD","LU1481599808.USD","LU0661504455.SGD","LU2324357040.USD","LU1019634622.SGD","LU0545039389.USD","LU1267930573.SGD","LU0969580561.USD","03165","IE00B3T34201.USD","LU1015430645.USD","LU1267930490.SGD","LU1267930227.SGD","LU0011850046.USD","LU0114720955.EUR","LU0345777659.USD","LU0203347892.USD","LU1019632923.USD","LU0553294199.USD","LU0128525689.USD","VSTM","IE0002141913.USD","LU0052756011.USD","LU0640478417.SGD","LU1023059063.AUD","LU0784385170.HKD","LU0823399737.USD","LU0784385840.USD","AZN.UK","LU0047473722.SGD","SG9999001176.SGD","IE00BJT1NW94.SGD","LU2279689827.SGD","LU2089284900.SGD","CRDF","LU0997586432.USD","SG9999013999.USD","LU2133065610.SGD","LU1078025761.USD"],"gpt_icon":1},{"id":"2546759747","title":"Cardiff Oncology Inc. Concluded Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546759747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546759747?lang=en_us&edition=fundamental","pubTime":"2025-06-27 04:31","pubTimestamp":1750969887,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc. held its Annual Meeting of Stockholders on June 26, 2025. During the meeting, all seven nominees for director were elected. The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2025, was ratified. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable to 12,150,000 shares was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 26, 2025, and is solely responsib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL9w0Lb4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiffoncology.com","stockEarnings":[{"period":"1week","weight":0.0753},{"period":"1month","weight":0.285},{"period":"3month","weight":0.2537},{"period":"6month","weight":-0.171},{"period":"1year","weight":-0.4276},{"period":"ytd","weight":-0.4078}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.003183},{"month":2,"riseRate":0.461538,"avgChangeRate":0.297462},{"month":3,"riseRate":0.384615,"avgChangeRate":0.093514},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.07213},{"month":5,"riseRate":0.461538,"avgChangeRate":0.052242},{"month":6,"riseRate":0.384615,"avgChangeRate":0.287657},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.07931},{"month":8,"riseRate":0.571429,"avgChangeRate":0.100833},{"month":9,"riseRate":0.285714,"avgChangeRate":0.016213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014863},{"month":11,"riseRate":0.357143,"avgChangeRate":0.032453},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.018928}],"exchange":"NASDAQ","name":"Cardiff Oncology, Inc.","nameEN":"Cardiff Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cardiff Oncology, Inc.,CRDF,Cardiff Oncology, Inc.股票,Cardiff Oncology, Inc.股票老虎,Cardiff Oncology, Inc.股票老虎国际,Cardiff Oncology, Inc.行情,Cardiff Oncology, Inc.股票行情,Cardiff Oncology, Inc.股价,Cardiff Oncology, Inc.股市,Cardiff Oncology, Inc.股票价格,Cardiff Oncology, Inc.股票交易,Cardiff Oncology, Inc.股票购买,Cardiff Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction